- Home
- ROMA vs CRDF Comparison
ROMA vs CRDF Comparison
Compare ROMA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- CRDF
- Stock Information
- Founded
- ROMA 2018
- CRDF 1999
- Country
- ROMA Hong Kong
- CRDF United States
- Employees
- ROMA N/A
- CRDF N/A
- Industry
- ROMA Savings Institutions
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROMA Finance
- CRDF Health Care
- Exchange
- ROMA Nasdaq
- CRDF Nasdaq
- Market Cap
- ROMA 150.7M
- CRDF 144.4M
- IPO Year
- ROMA 2024
- CRDF N/A
- Fundamental
- Price
- ROMA $3.31
- CRDF $2.00
- Analyst Decision
- ROMA
- CRDF Strong Buy
- Analyst Count
- ROMA 0
- CRDF 5
- Target Price
- ROMA N/A
- CRDF $11.10
- AVG Volume (30 Days)
- ROMA 47.5K
- CRDF 1.1M
- Earning Date
- ROMA 09-25-2025
- CRDF 11-06-2025
- Dividend Yield
- ROMA N/A
- CRDF N/A
- EPS Growth
- ROMA N/A
- CRDF N/A
- EPS
- ROMA N/A
- CRDF N/A
- Revenue
- ROMA $1,568,345.00
- CRDF $545,000.00
- Revenue This Year
- ROMA N/A
- CRDF N/A
- Revenue Next Year
- ROMA N/A
- CRDF N/A
- P/E Ratio
- ROMA N/A
- CRDF N/A
- Revenue Growth
- ROMA 23.21
- CRDF N/A
- 52 Week Low
- ROMA $0.54
- CRDF $1.90
- 52 Week High
- ROMA $4.66
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ROMA 54.30
- CRDF 34.76
- Support Level
- ROMA N/A
- CRDF $1.97
- Resistance Level
- ROMA $3.40
- CRDF $2.27
- Average True Range (ATR)
- ROMA 0.33
- CRDF 0.12
- MACD
- ROMA 0.01
- CRDF 0.03
- Stochastic Oscillator
- ROMA 97.38
- CRDF 27.03
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.